key: cord-0715200-zp5d2rey
authors: Groß, Rüdiger; Zanoni, Michelle; Seidel, Alina; Conzelmann, Carina; Gilg, Andrea; Krnavek, Daniela; Erdemci-Evin, Sümeyye; Mayer, Benjamin; Hoffmann, Markus; Pöhlmann, Stefan; Liu, Weimin; Hahn, Beatrice H.; Beil, Alexandra; Kroschel, Joris; Jahrsdörfer, Bernd; Schrezenmeier, Hubert; Kirchhoff, Frank; Münch, Jan; Müller, Janis A.
title: Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants
date: 2021-12-17
journal: EBioMedicine
DOI: 10.1016/j.ebiom.2021.103761
sha: d54d51b76322f764bb5526ff64c0de4840ef725e
doc_id: 715200
cord_uid: zp5d2rey

BACKGROUND: Heterologous COVID-19 vaccination regimens combining vector- and mRNA-based vaccines are already administered, but data on solicited adverse reactions, immunological responses and elicited protection are limited. METHODS: To evaluate the reactogenicity and humoral as well as cellular immune responses towards most prevalent SARS-CoV-2 variants after a heterologous ChAdOx1 nCoV-19 BNT162b2 prime-boost vaccination, we analysed a cohort of 26 clinic employees aged 25-46 (median 30.5) years who received a ChAdOx1 nCoV-19 prime followed by a BNT162b2 boost after an 8-week interval. Serological data were compared to a cohort which received homologous BNT162b2 vaccination with a 3-week interval (14 individuals aged 25-65, median 42). FINDINGS: Self-reported solicited symptoms after ChAdOx1 nCoV-19 prime were in line with previous reports and more severe than after the BNT162b2 boost. Antibody titres increased significantly over time resulting in strong neutralization titres two weeks after the BNT162b2 boost and subsequently slightly decreased over the course of 17 weeks. At the latest time point measured, all analysed sera retained neutralizing activity against the currently dominant Delta (B.1.617.2) variant. Two weeks post boost, neutralizing activity against the Alpha (B.1.1.7) and immune-evading Beta (B.1.351) variant was ∼4-fold higher than in individuals receiving homologous BNT162b2 vaccination. No difference was observed in neutralization of Kappa (B.1.617.1). In addition, heterologous vaccination induced CD4(+) and CD8(+) T cells reactive to SARS-CoV-2 spike peptides of all analysed variants; Wuhan-Hu-1, Alpha, Beta, Gamma (P.1), and Delta. INTERPRETATION: In conclusion, heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination is not associated with serious adverse events and induces potent humoral and cellular immune responses. The Alpha, Beta, Delta, and Kappa variants of spike are potently neutralized by sera from all participants and reactive T cells recognize spike peptides of all tested variants. These results suggest that this heterologous vaccination regimen is at least as immunogenic and protective as homologous vaccinations and also offers protection against current variants of concern. FUNDING: This project has received funding from the European Union's Horizon 2020 research and innovation programme, the German Research Foundation, the BMBF, the Robert Koch Institute (RKI), the Baden-Württemberg Stiftung, the county of Lower Saxony, the Ministry for Science, Research and the Arts of Baden-Württemberg, Germany, and the National Institutes of Health.

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants Introduction The first cases of the coronavirus disease 2019 (COVID- 19) were reported to the World Health Organization on December 31 st 2019, 1 and within 93 days the causative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had infected over 1 million people worldwide. 2 Only 250 days later, the first person received a COVID-19 vaccine outside a clinical trial. To date, vaccination is considered the key strategy for ending the pandemic. 3 Approved vaccines among others include the adenovirus-based ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca) and mRNA-based BNT162b2 (Comirnaty, BioNTech/ Pfizer), which induce humoral and cellular immunological responses 4À7 (and preprint: 8 ), showed high efficacy in clinical trials, 9, 10 and potent protection from COVID-19 in real-world settings. 11, 12 However, the occurrence of rare thrombotic events with thrombocytopenia after ChAdOx1 nCoV-19 vaccinations, especially in individuals younger than 60 years, associated with the generation of auto-platelet factor 4 antibodies, halted vaccination of this group with ChAdOx1 nCoV-19 in some countries. 13À15 As a consequence, several public health agencies recommended boost vaccinations of individuals already primed with ChAdOx1 nCoV-19 to be carried out in a heterologous regimen with an mRNA vaccine. 16 In some countries, however, such a regimen is still not applied due to limited data on safety and immunogenicity. Moreover, it remains unclear whether a heterologous boosting schedule is associated with similar 17À19 or greater 20 reactogenicity compared to homologous vaccination. Finally, while robust immune responses are elicited by heterologous vaccination regimens with a 8-12 week interval, 17À19,21 there is limited knowledge about humoral and cellular protection against the variants of concern (VOCs), especially the most prevalent Delta (B.1.617.2) variant. 19 ,21À23 Further, published studies have not investigated how immunity develops several months after vaccination. Here, we examined a cohort of 26 individuals (16 female, 10 male; median age 30.5, range who received ChAdOx1 nCoV-19 prime and, due to changing recommendations in Germany, 16 a BNT162b2 boost vaccination with a 56-60 day interval and evaluated solicited adverse reactions, humoral and cellular immune responses against several spike variants, including that

Evidence before this study Heterologous vaccination against COVID-19, combining vector-and mRNA-based vaccines, is now part of the applied vaccination regimens in several countries in response to changing recommendations and vaccine shortages. However, evidence on tolerability, immunogenicity or efficacy of such regimens especially against the Delta variant is limited.

Our study of a cohort of 26 clinic employees adds to the accumulating evidence that solicited adverse reactions for most participants receiving an 8-week interval BNT162b2 boost was lower compared to the ChAdOx1 nCoV-19 prime. Importantly, heterologous vaccination resulted in high levels of IgG, IgA, IgG/M, and potent neutralizing antibody titres. Sera obtained after full vaccination neutralized Alpha, Beta and Kappa SARS-CoV-2 spike variants with greater potency than after homologous BNT162b2 vaccination. In addition, neutralizing titres against Delta were detected in all participants 3 months after the boost vaccination. SARS-CoV-2 spikereactive CD4 + and CD8 + T cells were regularly elicited by this vaccination regimen, and also responded to Alpha, Beta, Gamma and Delta variants. In conclusion, we provide evidence that in young adults, vaccination with ChAdOx1 nCoV-19 and BNT162b2 in a heterologous prime-boost regimen is well-tolerated and induces potent Delta neutralizing antibody responses still detectable after 3 months as well as T cell reactivity also against variants.

Combined with published evidence on tolerability and immunogenicity of heterologous vaccination against COVID-19, combining vector-and mRNA-based vaccines is a promising alternative to homologous regimens. The high levels of neutralizing titres and potent T cell responses induced by this regimen, especially against the dominant Delta variant, may be highly beneficial in light of emerging variants showing increased immune evasion. These results thus have direct implications for policy makers, physicians and patients who are offered the choice of such a regimen and offer perspectives to boost immunity in future vaccine updates.

of the dominant Delta VOC up to 3 months after boost vaccination. We further compared serological parameters to a cohort which received homologous BNT162b2 vaccination with a 3-week interval (14 individuals aged 25-65, median 42; Appendix Table 1 ).

A cohort of 26 individuals aged 25-46 (median 30.5) years who received a ChAdOx1 nCoV-19 prime followed by a BNT162b2 boost after an 8-week interval were analysed for reactogenicity, antibody responses and T cell reactivity. The study size is the result of volunteers which could be enrolled at Ulm University Medical Centre prior to a scheduled prime vaccination date. Initial blood samples were taken up to 2 days before prime vaccination. Participants were eligible for recruitment if they had not been previously vaccinated against SARS-CoV-2 and were scheduled for a ChAdOx1 nCoV-19 prime vaccination. Prior SARS-CoV-2 infection was determined by medical history and measuring anti-SARS-CoV-2-nucleocapsid antibody levels. One convalescent individual was detected and excluded from all statistical analyses (Table 1) . Solicited adverse reactions after both prime and boost vaccination were selfreported and ranked by severity and duration. Blood samples were taken from all participants at several follow-up time points throughout the study and analysed for antibodies and T-cell reactivity against SARS-CoV-2 spike. Follow-up consists of collection of blood samples only and is ongoing as part of a long-term study for this cohort, data reported herein is reported up to 116 days after boost vaccination. As a comparative cohort, we performed a retrospective analysis of sera from individuals who received homologous BNT162b2 vaccination with a 3-week interval (14 individuals aged 25-65, median 42; Appendix Table 1 ). 24 

The study was approved by the ethics committee of Ulm university (99/21) and performed in compliance with the approval. Previously described sera from homologous BNT162b2 vaccinated individuals, 24 taken under approval by the ethics committee of Ulm university (31/ 21), were re-analysed for this study. All participants gave written informed consent.

Hospital employees who were scheduled for vaccinations volunteered for regular blood donations. Participants received a heterologous vaccination regimen because after their ChAdOx1 nCoV-19 prime vaccination, the German Standing Committee on Vaccination (STIKO) had changed the recommendation for individuals < 60 years of age to receive an mRNA vaccine as boost vaccination to avoid risk of thrombotic complications. 13, 16 At days -2/0 before vaccination, days 15-16, 30-37, 53-57 after ChAdOx1 nCoV-19 vaccination, and days 6-11, 14-19, 38-48 and 93-116 after heterologous BNT162b2 boost, blood was drawn into S-Monovette Ò Serum Gel (Sarstedt) or S-Monovette Ò K3 EDTA tubes. Sera from individuals vaccinated twice with BNT162b2 were obtained 13-15 days after the second dose (Appendix Table 1 ); these sera were previously described and re-analysed for this study. 24 Serum gel collection tubes were centrifuged at 1,500 £ g at 20°C for 15 min, aliquoted and stored at -20°C until further use. Peripheral blood mononuclear cells (PBMCs) were obtained from EDTA tubes using density gradient centrifugation by Pancoll human (Pan Biotech, Germany), and erythrocytes removed by ACK lysis buffer (Lonza, Walkersville, MD, U.S.A). Mononuclear cells were counted for viability using a Countess II Automated Cell Counter (Thermo Fisher) with trypan blue stain and were cryopreserved in aliquots of up to 1 £ 10 7 cells in 10% DMSO in heat-inactivated FCS.

Solicited adverse reactions (SAR) were self-reported by the participants via questionnaire following prime and boost vaccination. Participants were asked to list symptoms, their duration (< 1 h, few hours, one day or more than one day) and severity (mild (grade 1), moderate (grade 2), severe (grade 3)). Grading criteria were adapted from the US Department of Health and Human Services CTCEA (Common Terminology Criteria for Adverse Events, v4.03), 25 with grade 1-2 being considered for some symptoms, grade 1-3 for most. For calculation of cumulative SAR (cSAR) scores, the grades of all symptoms listed were summed up, with an additional score point added for each symptom that was experienced for more than one day (0-4).

IgG and IgA levels in serum were determined by anti-SARS-CoV-2 assay (Euroimmun), an ELISA which 

Prevention of SARS-CoV-2 spike RBD interaction with ACE2 by sera was evaluated by SARS-CoV-2 Surrogate Virus Neutralization Test Kit (GenScript) according to the manufacturer's instructions. To this end, sera were incubated with a peroxidase-conjugated RBD fragment and the mixture added to a human ACE2 coated plate, and unbound RBD washed away. Thereafter, substrate was added and the reaction stopped by stopping reagent. ODs at 450 nm were measured at a microplate reader. The inhibition score compared to the negative control was calculated as percentages. Scores <20% were considered negative and scores >20% positive.

Vero E6 (African green monkey, female, kidney; CRL-1586, ATCC, RRID:CVCL_0574) cells were grown in Dulbecco's modified Eagle's medium (DMEM, Gibco) which was supplemented with 2.5% heat-inactivated fetal calf serum (FCS), 100 units/ml penicillin, 100 µg/ ml streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1x non-essential amino acids. HEK293T (human, female, kidney; ACC-635, DSMZ, RRID: CVCL_0063) cells were grown in DMEM with supplementation of 10% FCS, 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine. All cells were grown at 37°C in a 5% CO 2 humidified incubator. Cell lines were recently purchased from the indicated companies and used without further authentication. All cell lines were regularly tested for mycoplasma contamination and remained negative. 24, 26, 27 Transfection of cells was carried out by Transit LT-1 (Mirus). Rhabdoviral pseudotype particles were prepared as previously described. 28 A replication-deficient VSV vector in which the genetic information for VSV-G was replaced by genes encoding two reporter proteins, enhanced green fluorescent protein and firefly luciferase (FLuc), VSVÃDG-FLuc 29 (kindly provided by Gert Zimmer, Institute of Virology and Immunology, Mittelh€ ausern, Switzerland) was used for pseudotyping. One day after transfection of HEK293T cells to express the viral glycoprotein, they were inoculated with VSVÃDG-FLuc and incubated for 1-2 h at 37°C. Then the inoculum was removed, cells were washed with PBS and fresh medium added. After 16-18 h, the supernatant was collected and centrifuged (2,000 £ g, 10 min, room temperature) to clear cellular debris. Cell culture medium containing anti-VSV-G antibody (I1-hybridoma cells; ATCC no. CRL-2700) was then added to block residual VSV-G-containing particles. Samples were then aliquoted and stored at -80°C. 

Funders had no role in study design, data collection, data analyses, interpretation, or writing of the report.

Prior to vaccination, one participant of our cohort of 26 individuals had a history of SARS-CoV-2 infection (Table 1) . Reactogenicity following prime and boost vaccination was evaluated in all study participants by examining self-reported solicited local and systemic symptoms according to a standardized questionnaire. Symptom severity (mild, moderate, severe) and duration (<1 hour, few hours, »1 day, > 1 day) is reported for each individual participant ( Figure S1a ) and percentage of participants (Figurere 1a,b) .

Both, prime and boost vaccination, induced mild to moderate solicited adverse reactions in most participants with 88.4% (23/26) reporting at least one mild or moderate symptom following the prime; 23/26 (88.4%) and 21/26 (80.8%) reporting at least one mild or moderate symptom following the mRNA boost (Figurere 1a,b) . Most common symptoms after prime vaccination with ChAdOx1 nCoV-19 were pain at the injection site (92.3%), fatigue (80.8%), headache (73.1%), chills (61.5%), myalgia (61.5%) and fever (61.5%). Following boost vaccination with BNT162b2, most participants again reported pain at the injection site (84.6%) and fatigue (84.6%), but chills (19.2%), myalgia (38.5%) and fever (19.2%) were less common. 23% of participants (6/26) reported at least one severe symptom following prime, 15.4% (4/26) after boost. Fatigue (7.7%) and headache (15.4% for prime, 3.8% for boost) were amongst symptoms reported as more severe for both doses, while myalgia was reported by 11.5% of participants following prime, but none after boost. Of note, after ChAdOx1 nCoV-19 prime, no participant developed platelet factor 4 autoantibodies 32 (Table 1) .

To get an estimate about how the overall reactogenicity was perceived, we compared cumulative solicited adverse reaction (cSAR) scores, and found that reactogenicity following prime with ChAdOx1 nCoV-19 was significantly (p = 0.008; paired t-test) higher than following boost with BNT162b2 (cSAR score median 11 and 6 respectively, Figurere 1c) . Individually, most participants (19/26, 73.07%) had milder reactions to boost compared to prime, similar as described for a homologous ChAdOx1 nCoV-19 vaccination. 6 6/26 (23.07%) of participants described more severe reactions to boost vaccination ( Figure S1b ). In this cohort of 26 participants, a non-significant trend (p > 0.1; Mann-Whitney-U test) towards higher cSAR scores reported by female participants was seen for both boost and prime vaccinations (Figurere 1d,e). No correlation was observed between reactogenicity and age (Figure S1c,d; |r| < 0.3; Spearman). Individual reactogenicity towards prime and boost vaccination showed a modest but significant correlation (Figurere 1f, r = 0.41; p = 0.039; Spearman).

We collected sera from participants 2 days before (-2) or on the day of (0) vaccination, and at days 15À16, 30À37, and 53À57 after ChAdOx1 nCoV-19 prime, and days 6À11 and 14À19 after BNT162b2 boost (64À65 or 72À73 after prime, respectively) to determine antibody responses (Figurere 2). Already 15À16 days after prime, 19/25 (76%) participants showed detectable anti-SARS-CoV-2-spike-IgG levels and 17/25 (65%) detectable IgA levels (Figurere 2a,b) . IgG levels peaked after 30À37 days and were detectable in 24/25 (96%) participants. Until days 53À57, IgG levels slightly decreased, consistent with previous results after single ChAdOx1 nCoV-19 dose. 5 Table 1 ) and median titres 1,086; range 498-3,660). Cumulative IgM/G titres correlated with IgG titres at each timepoint analysed post prime ( Figure S2a , Appendix Table 2 ). In addition, we followed up antibody titres over the course of 13-17 weeks (93-116 days) after boost, and confirmed that they are decreasing. However, they maintained a median titre of 2,039 (235 -5,926) that was still 1.9-fold higher than in homologous BNT162b2 vaccinated individuals 2 weeks post boost (p = 0.038; Mann-Whitney-U test).

Sera were also evaluated for their potential to inhibit SARS-CoV-2-spike-receptor binding domain/ACE2 interaction using a surrogate virus neutralization test (sVNT) (Figurere 2d). 15À16 days after ChAdOx1 nCoV-19 administration 13/25 (52%) participant sera showed ACE2 neutralizing activity, correlating significantly with IgG and IgM/G titres ( Figure S2a , Appendix Table  2 ). Median neutralization activity of the positive sera was 46% (range 32-97%). Until days 53À57, the number of participants with neutralizing sera increased to 19/26 (73%) and the median ACE2 neutralization to 62% (range 32-95%), again in correlation with IgG and IgM/ G values ( Figure S2a , Appendix Table 2 ). After BNT162b2 boost, all participants showed potent neutralization with a median of 97% (range 32-98%) after 6À11 days, and 98% (range 89-98%) after 14À19 days suggesting a strong and functional antibody response after heterologous vaccination in all participants.

The potency of neutralizing activity was further quantified using vesicular stomatitis virus (VSV)-based pseudoviruses carrying the SARS-CoV-2 spike protein of the SARS-CoV-2 Alpha (B.1.1.7) variant. This system faithfully recapitulates SARS-CoV-2 entry into cells and its inhibition. 26 days 53À58. Two weeks after the BNT162b2 boost, neutralizing activities were detected in all participants with a median titre of 2,744 (range 209-8,985). Of note, while for some individuals the titres further increased from week 1 to week 2 after BNT162b2 boost, it plateaued at titres > 1,000 for others ( Figure S3 ). At all time-points, neutralizing activity correlated with IgG or IgM/G titres ( Figure S2a , Appendix Table 2 ).

Remarkably, the median titre of these individuals was 3.9-fold higher than the median titre two weeks post boost of 14 individuals vaccinated with BNT162b2 in a homologous regimen 24 (709; range 305-1,806; p < 0.0001; Mann-Whitney-U test) suggesting stronger humoral protection after the heterologous vaccination. Multivariable analyses did not indicate sex or age as an important confounder for this effect (p > 0.05). Of Additionally, we evaluated the neutralizing activities of sera obtained 2 weeks post full vaccination against the immune evading variants Beta (B.1.351) and Kappa (B.1.617.1). Pseudovirus entry driven by Beta spike was neutralized with 2-fold lower potency (p < 0.021; Mann-Whitney-U test) compared to Alpha spike. However, it was still entirely blocked at higher doses with a median titre of 1,297 (range 252 -6,523). Neutralization of the Kappa spike was not reduced compared to Alpha spike (median titre of 1,309; range 150 À 13,252) (Figurere 2f; p = 0.65; Mann-Whitney-U test). Sera of individuals receiving two BNT162b2 immunizations showed lower neutralizing titres against all spike variants tested (Figurere 2f), suggesting stronger humoral protection after the heterologous vaccination also against VOCs. To analyse the neutralizing capacity of the sera against the dominant and thus most relevant Delta variant, we collected follow-up sera of the participants in week 5-7 and 13-17 (days 38-48 and 93-116) after the boost. We found that all sera neutralized the Delta variant, however, with lower titres than previously determined against Alpha and decreasing efficiency from 5-7 to 13-17 weeks post boost (Figurere 2g). Again, these titres correlated well with the IgM/IgG concentrations (Figurere 2c; Figure S2b ). In both cohorts , no correlation of neutralizing antibody titre (PVNT50) with age nor sex were observed ( Figure S4 ; |r| < 0.3, Spearman; p > 0.1, Mann-Whitney-U test).

To evaluate cellular immunity, we isolated peripheral blood mononuclear cells from blood samples provided by 21/26 participants before ChAdOx1 nCoV-19 prime, and 6À11 and 14-19 days post BNT162b2 boost (64-65 and 72-73 days post prime), considered as full vaccination according to the vaccination schedule. Cells were exposed to SARS-CoV-2 spike-spanning peptidepools and analysed for intracellular cytokines TNFa, IFNg, and IL-2 to determine spike-specific CD4 + and CD8 + T cell responses (Figurere 3, S5, S6 ). 6-11 days after boost, 68% of participants showed IFNy, TNFa, and/or IL-2 CD4 + T cell responses upon stimulation with Wuhan-Hu-1 SARS-CoV-2 spike peptides (Figurere 3a). After full vaccination, CD4 + T cells producing IFNg (median 0.055%, range 0.018-0.168), IL-2 (median 0.055%, range 0-0.134) or TNFa (median 0.057%; range 0.01 À 0.193) were significantly increased upon stimulation as compared to the pre-vaccination baseline (p < 0.05; mixed linear regression model). Spike-reactive CD4 + T cells were detected in 95% suggesting that most individuals developed a robust spike-specific T helper 1 (TH1) CD4 + T cell response post BNT162b2 boost. In addition, we observed an increase of spike-specific CD8 + T cells predominantly producing IFNg (median 0.092%, range 0 -0.665) and TNFa (median 0.055%, range 0 À 0.375) compared to pre-vaccination baseline samples in all previously uninfected participants (Figurere 3a; p < 0.001; mixed linear regression model). Levels of spike-specific CD8 + T cells producing IL-2 (median 0.01%, range 0-0.052) were lower, which is in agreement with responses reported after homologous BNT162b2 vaccination described in a preprint. 8 We then compared the response to SARS-CoV-2 spike variants Alpha, Beta, and Gamma (P.1) at day 6-11 after boost, and found that both CD4 + and CD8 + T cells showed IFNg responses to all spike variants (Figurere 3b), however less pronounced for TNFa and IL-2 ( Figure S6 c,d) . Upon emergence and rapid spread of SARS-CoV-2 Delta, we analysed the reactivity of T cells obtained day 14-19 post boost against this VOC. 94% of participants showed increased responses of CD4 + T cells upon stimulation with Delta spike peptides and all participants had Delta spike specific CD8 + T cells (Figurere 3c) . Thus, T cell reactivity against all five spike variants was found in all participants. Of note, reactivity of the CD4 + and CD8 + T cells of the convalescent individual did not increase after vaccination (Figurere 3a), indicating pre-existing cellular immunity. In conclusion, these findings show a robust humoral and cellular immune response after heterologous vaccination.

Heterologous prime-boost regimens have already been performed in several countries even though clinical studies had not been available at the time and studies on effectiveness have only recently begun to be evaluated. 35, 36 Based on the regulatory approvals for ChAdOx1 nCoV-19 and mRNA vaccines, the interval between prime and boost vaccinations ranges between 4-12 weeks. 37À39 For ChAdOx1 nCoV-19, a 12 week interval has been shown to result in stronger immune responses, 40 likely because the immunity against the vector wanes and the immunological memory matures. Accordingly, in Germany heterologous vaccinations were typically performed after 12 weeks. Existing vector immunity, however, is irrelevant in the context of a mRNA boost vaccination, on which basis our cohort received the boost after 8 weeks. This heterologous ChAdOx1 nCoV-19/BNT162b2 vaccination elicited strong IgM/G and IgA responses, potent neutralizing antibodies and T cell responses in all previously uninfected participants, while solicited adverse reactions to vaccination were as expected for a prime ChAdOx1 nCoV-19 vaccination and reduced following heterologous BNT162b2 boost.

In a homologous ChAdOx1 nCoV-19 vaccination regimen with an 28 day interval, the boost dose is associated with lower reactogenicity than the prime dose. 6 A previous study showed that a heterologous ChAdOx1 nCoV-19 prime BNT162b2 boost vaccination schedule with 4-week interval results in stronger reactogenicity after boost, 20 whereas studies with an 8-to 12-week interval did not confirm this effect. 17À19 We did not directly compare different vaccination schemes, as our comparative homologous BNT162b2 vaccination cohort was analysed retrospectively for serology and not polled for reactogenicity. Thus, we cannot draw definitive conclusions on quantitative differences, which might also depend on cohort age. 6 With an 8-week interval, we observed an overall milder reactogenicity following heterologous boost with BNT162b2 than after initial prime vaccination with ChAdOx1 nCoV-19 and no serious adverse events.

Our immunological data suggest that a heterologous vector-based/mRNA prime-boost schedule would be highly effective in preventing COVID-19, as neutralizing antibody levels correlate with immune protection from symptomatic SARS-CoV-2 infection 41 and CD8 + T cell responses have been associated with a mild disease course. 42, 43 Endpoint neutralizing antibody titres determined 2 weeks post boost were »4-fold higher than those detected upon homologous BNT162b2 vaccinations suggesting stronger humoral protection (Figurere 2e). Even though our statistical analyses do not identify possible confounders, this outcome might also depend on sex, age or the vaccination intervals between the two groups as the homologous BNT162b2 cohort was »10 years older in age, had higher fraction of male participants and was vaccinated in a three-week interval (Table 1; Appendix Table 1 ). Yet, this observation is in agreement with other studies 19, 21, 44 and suggests that ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination elicits particularly potent immune responses. 17, 18, 45 As reported for homologous vaccinations, 46 titres also decrease over time after heterologous vaccination. However, they remained high for three months post boost suggesting robust durable protection. Notably, the results might also be influenced by the young cohort age. Circumvention of vector immunity might also contribute to this high immunogenicity. 35 The BNT162b2 encoded spike sequence contains a two-proline mutation not present in ChAdOx1 nCoV-19, which stabilizes the spike protein in a pre-fusion confirmation. 10, 47 It is tempting to speculate that altered spike conformations between the vaccinations might improve humoral responses.

Neutralizing activity towards VOC Beta, previously reported to show partial evasion of vaccination-induced antibodies, 24, 48, 49 was slightly decreased compared to Alpha following heterologous vaccination, which agrees with recent data. 21 However, the titre was still higher than for Alpha after two doses of BNT162b2. Neutralization of emerging Kappa, reported to be the most efficient neutralization-evading strain of the B.1.617 lineage, 44 was not reduced compared to Alpha. Previous studies addressing heterologous vaccinations indicated that the Delta variant is equally sensitive to neutralization as Alpha. 22, 23, 45 We observed that in correlation with the IgM/IgG titres, neutralizing titres against Delta are decreasing over the course of 13-17 weeks but remain detectable in all analysed sera at the latest time points. This confirms a good prediction by IgM/IgG titres and indicates durable protection from the most prevalent Delta variant. Breakthrough infections of vaccinated individuals are associated with low neutralizing titres, 50 and a decline of the titre over time results in less effective SARS-CoV-2 neutralization. 46, 51 Thus, the fact that neutralizing titres after heterologous boost are high suggests efficient initial protection from breakthrough infections, also by the Delta variant. Ongoing and future studies addressing the decay kinetics will allow to determine the time after which a second boost might be most beneficial.

Secretory IgA responses at the mucosal site of SARS-CoV-2 entry are of particular interest with regard to prevention of virus transmission and (re-)infection. 52 We detected a general increase in serum IgA levels with strong variation between participants and a decrease over time after prime vaccination. Future studies, especially assessing IgA and secretory IgA levels and persistence at mucosal entry sites after boost are warranted to analyse potential mucosal protection after vaccination.

In all participants SARS-CoV-2 specific CD8 + or CD4 + T cells were detected 2 weeks after full vaccination. These effects were similar to those reported after a single ChAdOx1 nCoV-19 dose 5 and after homologous BNT162b2 vaccination as reported in a preprint. 8 This suggests that T cell responses are similarly effective after heterologous vaccination. Importantly, all donors showed some degree of T cell reactivity against the prevalent Delta variant. Similarly, responses against Alpha and most humoral immunity-evading VOCs Beta and Gamma were detectable suggesting a broad immune response. This is in line with previous findings that variants escaping humoral immunity are still recognized by reactive T cells indicating broad protection from SARS-CoV-2 on a cellular level, 10,53 also after heterologous vaccination.

In line with previous reports, 54,55 a single prime vaccination dose already elicited strong antibody responses in an individual participant who was previously tested SARS-CoV-2 positive. In this case, the observed neutralizing titres 2 weeks after prime were as high as the median titre of those receiving the homologous BNT162b2 vaccination. However, titres (IgM/G) further increased 8-fold after boost, suggesting that prime-boost might provide more potent and longer lasting protection also in convalescent patients. This agrees with a recent study 56 and seems important considering that the currently dominating Delta variant is causing breakthrough infections. 50 In conclusion, a heterologous vaccination regimen of ChAdOx1 nCov-19 prime, followed by BNT162b2 boost after 8 weeks for participants with a median age of 30.5 years was tolerable and effective. These results are encouraging and of significant interest for policy makers, physicians as well as individuals who have received or will receive this combination. This regimen provides flexibility for future vaccination strategies and will be useful for vaccine schedules during shortages. The perspective that heterologous vaccination induces neutralizing titres predictive of protection should be considered as a potential strategy to elicit particularly strong immune responses, e.g. in immunocompromised, highly exposed individuals, against Delta and upcoming VOCs, and for third doses of vaccination after previous homologous prime-boost regimen or vaccine updates against COVID-19. It will be interesting to clarify whether different spike conformations or of different variants are particularly effective. Similarly, whether other vector-or mRNA-based vaccine combinations or those based on other technologies are as effective needs to be addressed in future studies.

The study cohort of 26 participants is not large, but due to longitudinal sampling a comprehensive statistical evaluation could be performed. Self-reported adverse reactions can be subject to recall bias and indicated grades of severity are subject to personal and individual sensation. With a median age of 30.5 (range 25 -46) years, the results do not provide information on the elderly. However, our study offers insight into how the younger age group reacts to a heterologous vaccination regimen. This is of high significance, because individuals younger than 60 have regularly been primed with ChAdOx1 nCov-19 and are now offered heterologous boost vaccination. Our study group received the second vaccination after 8 weeks, which is within the range of recommendation of 4-12 weeks for homologous ChA-dOx1 nCov-19 vaccination. Humoral responses determined 15-17 after boost suggest ongoing protection but do not allow conclusions about longer-lasting immunity.

The authors have nothing to disclose. 

World Health Organization. Pneumonia of unknown cause À China

A global database of COVID-19 vaccinations

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Interim findings from first-dose mass COVID-19 vaccination rollout and COVID-19 hospital admissions in Scotland: a national prospective cohort study

AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (Combi-VacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination

Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Common terminology criteria for adverse events: (CTCAE)

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein

A Vesicular Stomatitis Virus Replicon-Based Bioassay for the Rapid and Sensitive Determination of Multi-Species Type I Interferon

3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelopeÀspecific plasma cells and humoral immunity in nonhuman primates

Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia

Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19ÀConvalescent Donors

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study

EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU

EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU

EMA recommends COVID-19 Vaccine Comirnaty for authorisation in the EU

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChA-dOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Immunogenicity and efficacy of heterologous ChadOx1/ BNT162b2 vaccination

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Viral targets for vaccines against COVID-19

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors

Two doses of the SARS-CoV-2 BNT162b2 vaccine enhances antibody responses to variants in individuals with prior SARS-CoV-2 infection 2021

We thank all participants for regular blood donations. We thank Nicola Schrott, Regina Burger, Jana Romana Fischer, Birgit Ott, Carolin Ludwig, Katrin Ring, Nadine Pfeifer, Maxine Rustler, Vivien Prex for skilful laboratory assistance. We thank Sarah Warth and Simona Ursu of the flow cytometry core facility for support with flow cytometric analysis. We thank the Robert Koch Institute (RKI) for financial support. This project has received funding from the European Union's Horizon 

Raw data are available from the corresponding author upon request.

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j. ebiom.2021.103761.